FY2025 EPS Estimates for AnaptysBio Lifted by HC Wainwright

AnaptysBio, Inc. (NASDAQ:ANAB) – Stock analysts at HC Wainwright increased their FY2025 earnings per share estimates for shares of AnaptysBio in a report released on Monday, November 24th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will earn ($0.60) per share for the year, up from their previous forecast of ($3.15). HC Wainwright has a “Buy” rating and a $51.00 price objective on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. HC Wainwright also issued estimates for AnaptysBio’s Q4 2025 earnings at $1.67 EPS, Q1 2026 earnings at ($1.02) EPS, Q2 2026 earnings at ($1.17) EPS, Q3 2026 earnings at ($1.62) EPS, Q4 2026 earnings at ($2.24) EPS, FY2026 earnings at ($6.31) EPS, FY2027 earnings at ($9.06) EPS, FY2028 earnings at ($4.42) EPS and FY2029 earnings at ($2.08) EPS.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $1.58. The firm had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.

ANAB has been the topic of a number of other research reports. Guggenheim raised their price target on shares of AnaptysBio from $90.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Wedbush restated an “outperform” rating and set a $50.00 target price on shares of AnaptysBio in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, October 8th. Stifel Nicolaus increased their price objective on AnaptysBio from $55.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, Barclays cut their price objective on AnaptysBio from $83.00 to $70.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, AnaptysBio has an average rating of “Moderate Buy” and an average price target of $59.30.

AnaptysBio Stock Up 1.6%

ANAB stock opened at $42.16 on Wednesday. The firm has a 50 day moving average of $32.81 and a two-hundred day moving average of $26.17. AnaptysBio has a 12 month low of $12.21 and a 12 month high of $43.31. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -14.95 and a beta of 0.16.

AnaptysBio announced that its Board of Directors has approved a share buyback program on Friday, November 21st that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the biotechnology company to buy up to 9.6% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its shares are undervalued.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Larson Financial Group LLC grew its stake in shares of AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 473 shares during the last quarter. Bessemer Group Inc. boosted its holdings in AnaptysBio by 950.0% in the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,292 shares during the period. US Bancorp DE grew its position in AnaptysBio by 126.5% in the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 979 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares during the period. Finally, Osaic Holdings Inc. grew its position in AnaptysBio by 11,630.0% during the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after buying an additional 2,326 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.